Microvascular dysfunction (small vessel disease) is the key cause of heart failure with preserved ejection fraction (preserved pumping capacity), found international team from Karolinska Institutet and AstraZeneca report in a study published in The European Heart Journal.
Heart failure is the most common reason for hospitalisation and causes much suffering.
Scientists at Karolinska Institutet, along with colleagues from AstraZeneca and four other groups in Sweden, the USA, Finland and Singapore have now conducted a study of over 200 patients with this type of heart failure.
‘Heart failure with preserved ejection fraction, which is one of the two main types of heart failure, lacks scientifically proven treatments and more research is needed to understand how the disease develops and is to be treated.’
The study involved the use of an innovative coronary imaging protocol developed by Professor Li-Ming Gan's research group in the IMED Biotech Unit in order to obtain a patient-friendly, cost-effective way to test coronary artery's ability to increase its blood flow (Coronary Flow Reserve - CFR) in addition to the traditional imaging approach to generate overall picture of the heart's structure and function.
"Being able to identify patients with heart failure with preserved ejection fraction is not only key to improving patient outcomes through early diagnosis but also for us to understand the causal mechanisms underlying the disease so we can develop future targeted therapies", says Professor Li-Ming Gan, Chief Scientist and Senior Medical Director, IMED Biotech Unit, AstraZeneca.
The results of the study, which is the first of its kind, show that 75 per cent of the patients had what is known as microvascular dysfunction. This is a disease in which the coronary artery shows no sign of narrowing or plaque in radiographs, but has damage to the endothelium that coats the inside of the blood vessels. The blood vessels do not work as they should, which can lead to adverse changes in the heart muscle. The researchers therefore draw the conclusion that microvascular dysfunction can be a critical underlying disease mechanism in patients with heart failure in which the ejection fraction is preserved.
"The results will be useful in identifying patients at risk of developing the disease, but above all they'll make an essential contribution to the development of drugs for patients with heart failure with preserved ejection fraction," says Lars Lund, Senior Consultant and Professor at Karolinska Institutet's Department of Medicine in Solna.
The results will be presented at the European Society of Cardiology (ESC) congress in Munich and are published in The European Heart Journal.